A

ACELYRIN Inc
NASDAQ:SLRN

Watchlist Manager
ACELYRIN Inc
NASDAQ:SLRN
Watchlist
Price: 4.29 USD 0.94% Market Closed
Market Cap: 430.4m USD
Have any thoughts about
ACELYRIN Inc?
Write Note

Profitability Summary

ACELYRIN Inc's profitability score is 27/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score
27/100
Profitability
Score

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
ACELYRIN Inc

Revenue
0 USD
Operating Expenses
-324.8m USD
Operating Income
-324.8m USD
Other Expenses
60.4m USD
Net Income
-264.4m USD

Margins Comparison
ACELYRIN Inc Competitors

Country Company Market Cap Operating
Margin
Net
Margin
US
ACELYRIN Inc
NASDAQ:SLRN
428.8m USD N/A N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
-21 040%
US
Abbvie Inc
NYSE:ABBV
314.1B USD
28%
9%
US
Amgen Inc
NASDAQ:AMGN
149.2B USD
19%
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.2B USD
40%
-5%
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD
38%
0%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
-392%
AU
CSL Ltd
ASX:CSL
135.2B AUD
26%
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88B USD
30%
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
-33%
NL
argenx SE
XBRU:ARGX
35B EUR
-22%
-14%
Country US
Market Cap 428.8m USD
Operating Margin N/A
Net Margin N/A
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Net Margin
-21 040%
Country US
Market Cap 314.1B USD
Operating Margin
28%
Net Margin
9%
Country US
Market Cap 149.2B USD
Operating Margin
19%
Net Margin
13%
Country US
Market Cap 122.2B USD
Operating Margin
40%
Net Margin
-5%
Country US
Market Cap 113.8B USD
Operating Margin
38%
Net Margin
0%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Net Margin
-392%
Country AU
Market Cap 135.2B AUD
Operating Margin
26%
Net Margin
18%
Country US
Market Cap 88B USD
Operating Margin
30%
Net Margin
34%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Net Margin
-33%
Country NL
Market Cap 35B EUR
Operating Margin
-22%
Net Margin
-14%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
ACELYRIN Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
ACELYRIN Inc
NASDAQ:SLRN
428.8m USD
-42%
-37%
-51%
-2 047%
FR
Pharnext SCA
OTC:PNEXF
6T USD
115%
-391%
275%
3 093%
US
Abbvie Inc
NYSE:ABBV
314.1B USD
56%
4%
15%
11%
US
Amgen Inc
NASDAQ:AMGN
149.2B USD
56%
5%
9%
10%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.2B USD
-3%
-2%
24%
-80%
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD
1%
0%
23%
13%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
AU
CSL Ltd
ASX:CSL
135.2B AUD
16%
7%
12%
9%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88B USD
17%
13%
13%
16%
US
Seagen Inc
F:SGT
39.3B EUR
-28%
-21%
-27%
-39%
NL
argenx SE
XBRU:ARGX
35B EUR
-8%
-7%
-12%
-31%
Country US
Market Cap 428.8m USD
ROE
-42%
ROA
-37%
ROCE
-51%
ROIC
-2 047%
Country FR
Market Cap 6T USD
ROE
115%
ROA
-391%
ROCE
275%
ROIC
3 093%
Country US
Market Cap 314.1B USD
ROE
56%
ROA
4%
ROCE
15%
ROIC
11%
Country US
Market Cap 149.2B USD
ROE
56%
ROA
5%
ROCE
9%
ROIC
10%
Country US
Market Cap 122.2B USD
ROE
-3%
ROA
-2%
ROCE
24%
ROIC
-80%
Country US
Market Cap 113.8B USD
ROE
1%
ROA
0%
ROCE
23%
ROIC
13%
Country US
Market Cap 94.1B EUR
ROE
-877%
ROA
-67%
ROCE
-73%
ROIC
-182%
Country AU
Market Cap 135.2B AUD
ROE
16%
ROA
7%
ROCE
12%
ROIC
9%
Country US
Market Cap 88B USD
ROE
17%
ROA
13%
ROCE
13%
ROIC
16%
Country US
Market Cap 39.3B EUR
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country NL
Market Cap 35B EUR
ROE
-8%
ROA
-7%
ROCE
-12%
ROIC
-31%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top